« Back
Home /
CGP-53353

CGP-53353

Item no.	HY-108600-25mg
Manufacturer	MedChem Express
CASRN	145915-60-2
Amount	25 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitor
Specific against	other
Purity	98.87
Formula	C20H13F2N3O2
Citations	[1]Yamamoto M, et al. Acute glucose-induced downregulation of PKC-betaII accelerates cultured VSMC proliferation. Am J Physiol Cell Physiol. 2000;279(3):C587-C595.
Smiles	O=C1NC(C2=C1C=C(NC3=CC=C(F)C=C3)C(NC4=CC=C(F)C=C4)=C2)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	DAPH-7
Available
Product Description	CGP-53353 (DAPH-7) is an potent PKC inhibitor with IC50s of 0.41 μM and 3.8 μM for PKCβII and PKCβI, respectively. CGP-53353 can inhibit glucose-induced cell proliferation and DNA synthesis in AoSMC and A10 cells. CGP-53353 can be used for researching atherosclerosis of diabetic patients[1].
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Metabolism-sugar/lipid metabolism
MolecularWeight	365.33
Clinical_Information	No Development Reported
Manufacturers Research_Area	Metabolic Disease; Cardiovascular Disease
Solubility	DMSO : ≥ 50 mg/mL
Manufacturers Target	DNA/RNA Synthesis; PKC
Isoform	PKCβ
Pathway	Cell Cycle/DNA Damage; Epigenetics; TGF-beta/Smad
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 25 mg

available

Request delivery time